## Abstract ## BACKGROUND: Humoralβmediated as well as cellβmediated immunity is compromised in myeloma patients receiving treatment. Immunocompromised patients are at risk of developing herpes zoster. There is evidence from clinical trials that bortezomib therapy is associated with a significant
Advances and controversies in the antiviral therapy of herpes zoster
β Scribed by A. L. Cunningham; D. E. Dwyer
- Publisher
- Springer
- Year
- 1996
- Tongue
- English
- Weight
- 255 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0934-9723
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
In a double blind trial adenine arabinoside (Vidarabine) and Idoxuridine (IDU) were tested in herpes simplex and herpes zoster infections. Adenine arabinoside covered 19 patients with HSV and 6 with HZ while IDU 19 with HSV and 6 with HZ. From the statistical analysis it was found that Vidarabine ac
The serological response of patients with acute herpes zoster was studied to determine whether a diagnosis could be made on a single serum sample, and whether this response was modified by treatment with antiviral and/or steroid therapy. The patients received one of four regimes of acyclovir and pre